Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: lazarre who wrote (844)	6/21/1999 6:22:00 PM
From: John Romeo	Read Replies (2) \| Respond to of 942

OK, I'll come out of the closet. I was prescribed Zocor since its approval and it worked ok,but didn't help my triglycerides. When Lipitor came out we did our own trial. We drew blood on Zocor and then stopped using it. Once the drug was gone, I was put on the smallest effective dose of Lipitor,which wasn't the case with Zocor.After 1 month we drew blood again. Lower triglycerides,within normal rates,lower HDL and lower overall cholesterol.A triple play. Good Bye Zocor.That is since the drug was made available.My levels haven't changed,quite normal. Check this out,there is a small biotech AVNT AvantImmunotherapy started today an athersclerosis vaccine Ph I trial.They say the drug has raised HDL and reduced plaque build up in lipid compromised sheep. They say it works, any volunteers?

To: lazarre who wrote (844)	6/29/1999 10:33:00 AM
From: Anthony Wong	Respond to of 942

Warner-Lambert Researchers Say Compound Stalls Tumors in Mice Bloomberg News June 28, 1999, 6 p.m. ET Warner-Lambert Researchers Say Compound Stalls Tumors in Mice Washington, June 28 (Bloomberg) -- Warner-Lambert Co. researchers have discovered a new drug that stalls the growth of cancerous tumors in mice, according to a study to be published tomorrow. The experimental compound, which hasn't yet been tested in humans, inhibited the growth of tumors by 53 percent to 79 percent in mice that were given varying doses. The research will be published in the July edition of the journal Nature Medicine. The drug, called PD 184352, works by stopping a cellular pathway called MAPK, which is responsible for a variety of different functions, including normal, healthy cell division. In some kinds of cancer, MAPK is over-stimulated, prompting cells to grow out of control. In an accompanying editorial, three researchers from the National Cancer Institute and the Van Andel Research Institute said the data ''show the importance of this pathway as a target in the war against cancer.'' The drug may also act in a similar way to anti-angiogenesis drugs, a promising class of drugs that stops tumor growth by cutting off a tumor's ability to grow blood vessels. MAPK plays a role in the growth of blood vessels, the process known as angiogenesis. The drug could run into problems because of the wide variety of processES that use the MAPK pathway. Inhibiting MAPK might important cellular functions, in addition to hindering tumor growth. Morris Plains, New Jersey-based Warner-Lambert shares fell 7/16 to close at 62 3/4.